GSK receives FDA approval for dissolvable Lamictal

05/11/2009 | Forbes

GlaxoSmithKline obtained FDA clearance to launch a soluble formulation of Lamictal, a treatment for epilepsy and bipolar disorder. Lamictal ODT is expected to be on the market by July in doses of 25, 50, 100 and 200 milligrams, GSK said.

View Full Article in:

Forbes

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Sr. Regulatory Specialist, Biotech Center of Expertise
BASF, The Chemical Co.
San Diego, CA
Food Lawyer
Cargill
Wayzata, MN
Director of Clinical Research
Regenesis Biomedical, Inc.
Scottsdale, AZ
Actuary
Meridian Health Plan
Detroit, MI
Assistant Vice President - Dental Director
MetLife
Bridgewater, NJ